We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




TB Blood Test Could Detect Millions of Silent Spreaders

By LabMedica International staff writers
Posted on 26 Mar 2024

Tuberculosis (TB) is the world's deadliest infectious disease, claiming over one million lives annually as reported by the World Health Organization. More...

TB's transmission occurs through the air when an infected person coughs or sneezes, releasing minute droplets that can affect not just the lungs but any body part. The fight against TB's spread is significantly hampered by the current testing methods, which are not only slow but also depend on specialized equipment and laboratory settings. Consequently, nearly three million TB cases went undetected last year, predominantly in developing nations, with a third of infected individuals remaining undiagnosed and, thus, contagious. In a significant development, scientists have advanced towards developing a blood test capable of detecting millions of people who are unknowingly transmitting TB.

In a pioneering study conducted by the University of Southampton (Southampton, UK), researchers have identified a specific group of biological markers present in high levels in individuals who are infectious. This discovery holds the promise of a simple diagnostic test capable of identifying and halting the spread of the disease, which affects an estimated 10 million people each year. Collaborating with international experts, these scientists performed the most detailed examination of blood markers associated with this bacterial infection. Utilizing an innovative approach, they identified six proteins that show a high degree of accuracy in identifying individuals with active TB.

The research team analyzed blood proteins from people with active TB located in Africa and South America, comparing these biomarkers against those found in healthy individuals and others with lung infections. They discovered 118 proteins that varied markedly between these groups. From these, they narrowed down to six proteins which they found could be used to effectively differentiate individuals with contagious TB from those who are healthy or have other lung ailments. This breakthrough finding paves the way for the development of a TB test which could be as simple as the lateral flow tests widely used during the recent pandemic.

“In our study, we combined a new measurement technique with deep mathematical analysis to identify these six new markers of TB disease,” said Dr. Hannah Schiff, a respiratory expert at Southampton. “It could lead to a transformative alternative to diagnosing the condition – a simple test that detects proteins in the bloodstream whose levels differ between people with TB, healthy individuals, and those suffering from other respiratory illnesses.”

Related Links:
University of Southampton


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.